Lenvatinib Plus Tislelizumab and CapeOX as First-Line Treatment for Advanced GC/GEJC With Positive PD-L1 and Low TMEscore
Clinical trial NCT06157996 · RECRUITING
Trial details
- NCT number
- NCT06157996
- Sponsor
- Nanfang Hospital, Southern Medical University
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-06-01
- Primary completion
- 2026-08-01
- Enrollment
- 92
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.